{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.120","pValueComment":"P-value is for comparison of the superiority of the LY3009104 dose level vs. placebo for the ordinal levels of response - Week 12. A priori p-value significance threshold: 1-sided ≤0.10.","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciNumSides":"TWO_SIDED","groupIds":["OG001","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.012","pValueComment":"P-value is for comparison of the superiority of the LY3009104 dose level vs. placebo for the ordinal levels of response - Week 12. A priori p-value significance threshold: 1-sided ≤0.10.","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciNumSides":"TWO_SIDED","groupIds":["OG002","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is for comparison of the superiority of the LY3009104 dose level vs. placebo for the ordinal levels of response - Week 12. A priori p-value significance threshold: 1-sided ≤0.10.","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciNumSides":"TWO_SIDED","groupIds":["OG003","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is for comparison of the superiority of the LY3009104 dose level vs. placebo for the ordinal levels of response - Week 12. A priori p-value significance threshold: 1-sided ≤0.10.","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"46"},{"groupId":"OG003","value":"40"},{"groupId":"OG004","value":"16"}]}],"title":"Good Response - Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"63"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"35"}]}],"title":"Moderate Response - Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"49"}]}],"title":"No Response - Week 12"},{"categories":[{"measurements":[{"comment":"Participants were not dosed with 1 mg LY3009104 after Week 12, therefore percentage was not calculated.","groupId":"OG000","value":"NA"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"42"},{"groupId":"OG003","value":"46"},{"comment":"Participants were not dosed with placebo after Week 12, therefore percentage was not calculated.","groupId":"OG004","value":"NA"}]}],"title":"Good Response - Week 24"},{"categories":[{"measurements":[{"comment":"Participants were not dosed with 1 mg LY3009104 after Week 12, therefore percentage was not calculated.","groupId":"OG000","value":"NA"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"42"},{"groupId":"OG003","value":"32"},{"comment":"Participants were not dosed with placebo after Week 12, therefore percentage was not calculated.","groupId":"OG004","value":"NA"}]}],"title":"Moderate Response - Week 24"},{"categories":[{"measurements":[{"comment":"Participants were not dosed with 1 mg LY3009104 after Week 12, therefore percentage was not calculated.","groupId":"OG000","value":"NA"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"22"},{"comment":"Participants were not dosed with placebo after Week 12, therefore percentage was not calculated.","groupId":"OG004","value":"NA"}]}],"title":"No Response - Week 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"52"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"98"}],"units":"Participants"}],"description":"EULAR28 categorizes clinical response based upon improvement since baseline in DAS modified to include the 28-joint count (DAS28) and post-baseline DAS28. DAS28 consists of a composite score of the following variables: TJC28, SJC28, CRP, and Patient's Global Assessment of their Disease Activity (patient's global VAS). DAS28 scores range from 1.0-9.4. EULAR28 categories include: No Response (improvement in DAS28 of ≤0.6 units or post-baseline DAS28 score \\>5.1 with improvement by ≤1.2 units), Moderate Response (post-baseline DAS28 ≤5.1 with improvement by \\>0.6 units but ≤1.2 units or post-baseline DAS28 score \\>3.2 with improvement by \\>1.2 units), and Good Response (post-baseline DAS28 score ≤3.2 with improvement by \\>1.2 units).","groups":[{"description":"1 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG000","title":"1 mg LY3009104"},{"description":"2 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nMTX was administered orally as background therapy.","id":"OG001","title":"2 mg LY3009104"},{"description":"4 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nMTX was administered orally as background therapy.","id":"OG002","title":"4 mg LY3009104"},{"description":"8 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nMTX was administered orally as background therapy.","id":"OG003","title":"8 mg LY3009104"},{"description":"Placebo administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG004","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"All randomized participants who received study drug in Parts A and B and had EULAR28 evaluated at analysis time points.","reportingStatus":"POSTED","timeFrame":"Baseline through Weeks 12 and 24","title":"Percentage of Responders According to European League Against Rheumatism Responder Index Based on 28-joint Count (EULAR28) Baseline Through Weeks 12 and 24","type":"SECONDARY","unitOfMeasure":"percentage of participants"}